What’s Next for Drug Validation in the Age of Precision Medicine

To live in a world where all people could access new drugs the current drug discovery cost has to be reduced. 

In fact, a paradigm shift is needed in the way of collecting data: switch from Randomized Control Trials to Patient Generated Healthcare Data.

Today 15% of the rare disease has no FDA approved therapy partly because it is very hard to recruit patient. It represents over 350 millions people all around the world. If the has to be changed, it would need:

  • a new trade off between research focus and compassion for rare disease.
  • making real world data regulatory grade

Read more about the future of drug validation in the Age of precision medicine.

Download document